Description

CJC-1295 with DAC 5MG

We provide CJC-1295 with DAC as a 5MG research peptide with a stated 99.1% purity. Furthermore, this modified growth hormone-releasing hormone analog incorporates a Drug Affinity Complex designed to extend its interaction with circulating albumin. Consequently, researchers have investigated its prolonged pharmacokinetic profile and its effects on growth hormone and IGF-1 secretion. Published research has demonstrated sustained increases in both hormones following experimental administration of CJC-1295.

CJC-1295 with DAC Key Attributes

• Brand: AvigenLab
• Product Name: CJC-1295 with DAC
• Quantity: 5MG
• Stated Purity: 99.1%
• Molecular Type: Modified GHRH Analog
• Peptide Length: 29 Amino Acids
• Drug Affinity Complex: Present
• Product Format: Vial
• Classification: Research Use Only
• Human Use: Not For Human Use

CJC-1295 with DAC Product Overview

We provide CJC-1295 with DAC for research involving growth hormone secretion, GHRH receptor signaling, pituitary somatotroph activity, IGF-1 regulation, and peptide pharmacokinetics. Moreover, the Drug Affinity Complex differentiates this formulation from shorter-acting GHRH analog configurations by promoting albumin association and extending systemic exposure. Research in healthy adults found an estimated half-life of approximately 5.8–8.1 days, alongside sustained GH and IGF-I responses.

Additionally, the published research demonstrated dose-dependent increases in mean plasma GH and IGF-I concentrations. Therefore, the compound provides a well-characterized research subject for investigating prolonged GHRH-related endocrine signaling.

Researchers can explore additional materials through our Online Store.

CJC-1295 with DAC Product Identification

We identify CJC-1295 with DAC through its 5MG quantity, modified GHRH analog identity, Drug Affinity Complex configuration, stated 99.1% purity, and vial presentation. PubChem identifies CJC-1295 as a maleimido derivative of human GHRH(1-29) and lists a molecular weight of 3,647.2 g/mol for its recorded structure.

Accordingly, the molecular identity, structural configuration, quantity, purity designation, and physical format provide clear reference points for laboratory inventory and product documentation.

Product Category

We classify CJC-1295 with DAC within our research peptide collection for endocrine, growth-hormone, and peptide pharmacokinetic investigations. Moreover, the compound’s modified structure makes it particularly relevant to studies examining how peptide modification can influence circulating exposure and hormone responses.

Furthermore, published research has examined the compound in controlled human studies, measuring GH and IGF-I concentrations alongside pharmacokinetic parameters. Consequently, researchers have a substantial scientific foundation for examining its relationship with prolonged endocrine signaling.

Scientific Characteristics

The molecular structure of CJC-1295 with DAC derives from human GHRH(1-29) and incorporates a Drug Affinity Complex that facilitates albumin binding. As a result, the modification substantially changes the compound’s circulating behavior compared with conventional short-duration GHRH structures. PubChem records CJC-1295 with the molecular formula C₁₆₅H₂₆₉N₄₇O₄₆ and molecular weight of 3,647.2 g/mol.

Furthermore, albumin association provides an important feature of the compound’s pharmacokinetic profile. Meanwhile, research has demonstrated prolonged exposure together with sustained GH and IGF-I responses. Therefore, the molecule offers a defined research model for examining relationships between peptide structure, pharmacokinetics, receptor signaling, and endocrine responses.

Research Applications

We position CJC-1295 with DAC for research involving GHRH receptor signaling, growth hormone secretion, IGF-1 regulation, pituitary somatotroph activity, endocrine physiology, peptide pharmacokinetics, and prolonged hormone-response pathways.

Additionally, experimental studies have demonstrated increases in mean plasma GH concentrations lasting six days or more after a single experimental administration, while IGF-I concentrations increased for approximately nine to eleven days. Consequently, researchers can examine both the acute and extended characteristics of GHRH-related endocrine signaling.

Nevertheless, experimental responses can vary according to research model, formulation, exposure conditions, and measured endpoint. Accordingly, researchers should evaluate individual findings within their specific experimental context.

Product Configuration

We provide CJC-1295 with DAC in a 5MG vial carrying a stated 99.1% purity designation. Furthermore, the defined quantity, modified GHRH identity, DAC configuration, and physical presentation establish straightforward reference points for laboratory inventory.

Additionally, this individual-peptide configuration distinguishes the product from our CJC no DAC and CJC/Ipamorelin combination presentations. Consequently, researchers can organize the material according to its specific molecular configuration and product format.

Product Features

The primary features of CJC-1295 with DAC include a 5MG quantity, 99.1% stated purity, modified GHRH structure, Drug Affinity Complex, and clearly defined research-use presentation.

Moreover, the product label communicates Not For Human Use | Research Use Only. Furthermore, the DAC configuration provides the defining structural characteristic associated with the compound’s extended pharmacokinetic profile. Published research supports this distinction by reporting an estimated half-life measured in days rather than hours.

Product Specifications

*Molecular identity information corresponds to the CJC-1295 structure recorded by PubChem.

Intended Research Context

We identify the material as Research Use Only and Not For Human Use. Accordingly, our documentation focuses on laboratory investigation rather than therapeutic or consumer applications.

In particular, researchers can examine the compound within experimental systems involving GHRH receptor activity, GH secretion, IGF-1 regulation, endocrine feedback, and peptide pharmacokinetics. Furthermore, controlled human research has investigated CJC-1295’s effects on GH and IGF-I concentrations and its pharmacokinetic characteristics.

Nevertheless, experimental findings do not automatically establish therapeutic outcomes. Therefore, we maintain a clear distinction between documented research observations and clinical claims.

Packaging Information

We present the product in a clearly labeled 5MG vial featuring our AvigenLab product presentation. The packaging identifies the compound, displays the 5MG quantity, communicates the stated 99.1% Purity, and identifies the material as Not For Human Use | Research Use Only.

Additionally, the vial format provides straightforward identification within our research catalog. You can also explore related materials through our Catalog.

Regulatory Information

We classify the product as Research Use Only and maintain the Not For Human Use designation throughout our product documentation. Accordingly, published studies concerning CJC-1295 do not constitute regulatory approval for this specific AvigenLab presentation.

Moreover, research involving CJC-1295 has examined pharmacokinetics, GH secretion, IGF-I responses, and safety within defined experimental protocols. Consequently, we document the material according to its molecular identity, research relevance, and product specifications without presenting experimental observations as established therapeutic claims.

Storage and Handling

We recommend following the storage and handling conditions specified in the applicable AvigenLab product documentation. Because peptide stability can depend on formulation, packaging, environmental exposure, and other product-specific variables, we avoid assigning unsupported storage parameters.

Furthermore, researchers should maintain appropriate laboratory handling practices and follow the product-specific documentation associated with the material. Consequently, this approach supports consistent laboratory management without introducing assumptions about conditions that may vary between formulations.

Market Availability

Our CJC-1295 with DAC 5MG presentation provides a defined individual research peptide configuration within our product collection. The quantity, stated purity, modified GHRH identity, DAC configuration, vial format, and Research Use Only designation create clear reference points for laboratory inventory.

Moreover, the compound has an established research history within endocrinology and peptide pharmacokinetics. Likewise, controlled studies have documented prolonged GH and IGF-I responses following experimental administration, making the compound relevant to continued investigation of long-acting GHRH analogs.

Product Reference

Our CJC-1295 with DAC 5MG presentation provides a defined modified GHRH research peptide carrying a stated 99.1% purity designation. We document the material according to its 29-amino-acid classification, Drug Affinity Complex, molecular characteristics, vial configuration, endocrine research applications, and Research Use Only status.

Consequently, the product provides researchers with a clearly identified material for investigating GHRH receptor activity, pituitary somatotroph signaling, growth hormone secretion, IGF-1 regulation, and peptide pharmacokinetics. Furthermore, the published pharmacokinetic profile provides a useful foundation for studying how structural modification can influence peptide exposure and sustained endocrine responses.